Urologic Oncology: Seminars and Original Investigations
Volume 25, Issue 2 , Pages 101-109, March 2007

Survival benefit for early hormone ablation in biochemically recurrent prostate cancer☆

  • Todd C. Tenenholz, M.D.

      Affiliations

    • Department of Radiation Oncology, Medical College of Virginia Hospitals, Virginia Commonwealth University, Richmond, VA 23298-0058, USA
    • ,
  • Christian Shields, M.A.

      Affiliations

    • Department of Radiation Oncology, Medical College of Virginia Hospitals, Virginia Commonwealth University, Richmond, VA 23298-0058, USA
    • ,
  • V. Ramakrishnan Ramesh, Ph.D.

      Affiliations

    • Department of Biostatistics, Medical College of Virginia Hospitals, Virginia Commonwealth University, Richmond, VA 23298, USA
    • ,
  • Oscar Tercilla, M.D.

      Affiliations

    • Department of Radiation Oncology, Medical College of Virginia Hospitals, Virginia Commonwealth University, Richmond, VA 23298-0058, USA
    • Department of Radiation Oncology, Hunter-Holmes McGuire Veterans Affairs Medical Center, Richmond, VA 23249, USA
    • ,
  • Michael P. Hagan, M.D.

      Affiliations

    • Department of Radiation Oncology, Medical College of Virginia Hospitals, Virginia Commonwealth University, Richmond, VA 23298-0058, USA
    • Department of Radiation Oncology, Hunter-Holmes McGuire Veterans Affairs Medical Center, Richmond, VA 23249, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1-804-828-2795 or +1-804-628-1032; fax: +1-804-828-6042.

Received 14 November 2005; received in revised form 1 March 2006; accepted 2 March 2006.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

☆ This work was supported by the Berlex Oncology Foundation for a clinical biostatistics training grant for T.C.T.

PII: S1078-1439(06)00060-3

doi:10.1016/j.urolonc.2006.03.002

Urologic Oncology: Seminars and Original Investigations
Volume 25, Issue 2 , Pages 101-109, March 2007

Article Tools

* Image Usage & Resolution